|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0028754,
umls-concept:C0304868,
umls-concept:C0439831,
umls-concept:C0681850,
umls-concept:C0870432,
umls-concept:C1313386,
umls-concept:C1550501,
umls-concept:C1555465,
umls-concept:C1705417,
umls-concept:C1706203,
umls-concept:C1979963,
umls-concept:C2003903,
umls-concept:C2349001,
umls-concept:C2697811,
umls-concept:C2825028
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2005-9-9
|
|
pubmed:abstractText |
This study compared the pharmacokinetics and pharmacodynamics of insulin glulisine, insulin lispro, and regular human insulin in obese subjects.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0947-7349
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
113
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
435-43
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:16151977-Adult,
pubmed-meshheading:16151977-Blood Glucose,
pubmed-meshheading:16151977-Double-Blind Method,
pubmed-meshheading:16151977-Female,
pubmed-meshheading:16151977-Humans,
pubmed-meshheading:16151977-Hypoglycemic Agents,
pubmed-meshheading:16151977-Injections, Subcutaneous,
pubmed-meshheading:16151977-Insulin,
pubmed-meshheading:16151977-Insulin Lispro,
pubmed-meshheading:16151977-Male,
pubmed-meshheading:16151977-Middle Aged,
pubmed-meshheading:16151977-Obesity,
pubmed-meshheading:16151977-Time
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects.
|
|
pubmed:affiliation |
Aventis Pharma Deutschland GmbH, Industriepark Höchst, Frankfurt am Main. Reinhard.Becker@sanofi-aventis.com
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
